WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 203071
Description: UNBS5162 is a novel naphthalimide that binds to DNA by intercalation and suppresses CXCL chemokine elaboration. In vivo UNBS5162 after repeat administration significantly increased survival in orthotopic human prostate cancer models. Results obtained by the National Cancer Institute (NCI) using UNBS3157 and UNBS5162 against the NCI 60 cell line panel did not show a correlation with any other compound present in the NCI database, including amonafide, thereby suggesting a unique mechanism of action for these two novel naphthalimides.
MedKoo Cat#: 203071
Chemical Formula: C17H18N4O3
Exact Mass: 326.13789
Molecular Weight: 326.34982
Elemental Analysis: C, 62.57; H, 5.56; N, 17.17; O, 14.71
Synonym: UNBS-5162, UNBS 5162, UNBS5162
IUPAC/Chemical Name: 1-(2-(2-(dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)urea
InChi Key: WCKZRLOUKYFJDY-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H18N4O3/c1-20(2)6-7-21-15(22)12-5-3-4-10-8-11(19-17(18)24)9-13(14(10)12)16(21)23/h3-5,8-9H,6-7H2,1-2H3,(H3,18,19,24)
SMILES Code: O=C(N)NC1=CC2=CC=CC(C(N(CCN(C)C)C3=O)=O)=C2C3=C1
The MTD or dose-limiting toxicity for UNBS5162 was not reached due to the magnitude of QTc prolongation at the highest dose of 234 mg/m(2)/week that led to study termination. ( Int J Clin Oncol. 2013 Oct;18(5):934-41.)
1: Mahadevan D, Northfelt DW, Chalasani P, Rensvold D, Kurtin S, Von Hoff DD, Borad MJ, Tibes R. Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. Int J Clin Oncol. 2013 Oct;18(5):934-41. doi: 10.1007/s10147-012-0475-8. Epub 2012 Oct 11. PubMed PMID: 23053399.